Study Details

Back to Search Results

A study of ELIGARD® in hormone-dependent prostate cancer patients

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03035032

Astellas Study ID

The unique identification code given by the study sponsor.

7015-MA-3072

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Prostate Cancer

Phase

These clinical trials happen after a drug or treatment has been approved for patients to take. Clinical trials in phase 4 usually take place over many years because researchers want to learn about long term use and safety of a drug or treatment.

Phase 4

Age

18 null - N/A

Sex

Male

Product

leuprorelin

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jun 2017 - Nov 2019

Masking

None (Open Label)

Enrollment number

107

A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study of ELIGARD® in hormone-dependent prostate cancer patients? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site VN08002

Ho Chi Minh City, Vietnam

Site PH04002

San Juan, Philippines

Site MY03001

Kuala Lumpur, Malaysia

Site SG05001

Singapore, Singapore

Site TH07004

Hat Yai, Thailand

Site TW06001

Taichung, Taiwan, Province of China

Site TW06003

Taipei, Taiwan, Province of China

Site SG05002

Singapore, Singapore

Site TH07001

Muang, Thailand

Site TW06002

Taichung, Taiwan, Province of China

Site PH04001

Makati City, Philippines

Site TH07002

Bangkok, Thailand

Site HK01002

Hong Kong, Hong Kong

Site HK01001

Hong Kong, Hong Kong

Site PH04003

Manila, Philippines

Site TH07003

Bangkok, Thailand

Site MY03002

Batu Caves, Malaysia

Site SG05003

Singapore, Singapore

Site ID02001

Jakarta, Indonesia

Site VN08001

Ho Chi Minh City, Vietnam

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo